Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.71 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.71 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.62 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.59 |
| ▸ | DRD1 | P21728 | 2/20 | 0.55 |
| ▸ | DRD5 | P21918 | 2/20 | 0.55 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8247399 | 0.94 | ESR1 (0.63) | ESR1ESR2ABHD6CA1CA2 | |
| SCHEMBL10351344 | 0.91 | ESR1 (0.62) | ESR1ESR2ABHD6CA1CA2 | |
| SCHEMBL11295872 | 0.88 | ESR1 (0.71) | ESR1ESR2ABHD6CA1CA2 | |
| SCHEMBL14590586 | 0.87 | ESR1 (0.57) | ESR1ESR2ABHD6CA1CA2 | |
| SCHEMBL29100405 | 0.87 | NOTUM (0.58) | ESR1ESR2ABHD6CA1CA2 | |
| SCHEMBL5523403 | 0.84 | CA1 (0.80) | ESR1ESR2ABHD6CA1CA2 | |
| SCHEMBL10400059 | 0.83 | ESR1 (0.64) | ESR1ESR2ABHD6CA1CA2 | |
| SCHEMBL3895230 | 0.83 | ESR1 (1.00) | ESR1ESR2ABHD6CA1CA2 | |
| SCHEMBL8239825 | 0.82 | CA1 (0.72) | ESR1ESR2ABHD6CA1CA2 | |
| SCHEMBL15755296 | 0.82 | ESR2 (0.72) | ESR1ESR2ABHD6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015158310-A1 | TYROSINE KINASE INHIBITOR AND USES THEREOF | 山东轩竹医药科技有限公司 | 2015-10-22 | — | — | WO | disclosed |
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | disclosed |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | ANALYTECON S.A. (CH) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | ESR1 1491/4885ESR2 2573/4885ABHD6 2406/4885 |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | EGFR, ERBB2, ABL1 | ESR1 1491/4885ESR2 2573/4885ABHD6 2406/4885 |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | IGF1R, INSR, GPR119 | ESR1 640/4885ESR2 169/4885ABHD6 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.